FRNRX
Price
$46.59
Change
-$0.22 (-0.47%)
Updated
Sep 18 closing price
Net Assets
554.52M
RSNRX
Price
$66.32
Change
+$1.32 (+2.03%)
Updated
Sep 17 closing price
Net Assets
634.93M
Interact to see
Advertisement

FRNRX vs RSNRX

FRNRX vs RSNRX Comparison Chart in %
View a ticker or compare two or three
VS
FRNRX vs. RSNRX commentary
Sep 19, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FRNRX is a Hold and RSNRX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RSNRX has more cash in the bank: 635M vs. FRNRX (555M). RSNRX pays higher dividends than FRNRX: RSNRX (3.24) vs FRNRX (1.30). FRNRX was incepted earlier than RSNRX: FRNRX (31 years) vs RSNRX (31 years). RSNRX (1.51) is less costly to investors than FRNRX (0.97). RSNRX is a more actively managed with annual turnover of: 50.00 vs. FRNRX (27.09). RSNRX (6%) and FRNRX (6%) have equivalent initial investment costs. FRNRX has a lower initial minimum investment than RSNRX: FRNRX (1000) vs RSNRX (2500). RSNRX annual gain was more profitable for investors over the last year : 56.58 vs. FRNRX (41.80). RSNRX return over 5 years is better than : 251.70 vs. FRNRX (151.81).
FRNRXRSNRXFRNRX / RSNRX
Total Expense Ratio0.961.4865%
Annual Report Gross Expense Ratio0.971.5164%
Fund Existence31 years31 years-
Gain YTD28.14130.05294%
Front Load6%6%96%
Min. Initial Investment1000250040%
Min. Initial Investment IRAN/AN/A-
Net Assets555M635M87%
Annual Yield % from dividends1.303.2440%
Returns for 1 year41.8056.5874%
Returns for 3 years64.79115.6456%
Returns for 5 years151.81251.7060%
Returns for 10 years110.79235.9747%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CM114.871.09
+0.96%
Canadian Imperial Bank of Commerce
AMRC23.750.05
+0.21%
Ameresco
LSTR170.29-0.85
-0.50%
Landstar System
CUE37.05-0.79
-2.09%
Cue Biopharma Inc.
TCRX0.31-0.02
-6.48%
TScan Therapeutics